Astellas Pharma (FRA:YPHA) FFO


FRA:YPHA Astellas Pharma Inc FRA:YPHA
82 GF Score
Price €11.30
GF Value €11.46
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma FFO?

FFO (Funds from operations) only applies to REITs.

FRA:YPHA
82GF Score
Astellas Pharma Inc FRA:YPHA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Astellas Pharma (FRA:YPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of €11.30 is trading 1.4% below its estimated GF Value™ of €11.46. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for FRA:YPHA:

  • FFO:
  • GF Value™: €11.46 vs. price of €11.30 (1.4% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the FRA:YPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
82GF Score

Get the complete analysis for FRA:YPHA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.30
Price
€11.46
GF Value